ArticlePharmaceutical research2002
On the transport of lipoplexes through cystic fibrosis sputum.
Article in Pharmaceutical research, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 34 citations in OpenAlex.
- Enhancing nanoparticle penetration through airway mucus to improve drug delivery efficacy in the lung.Expert opinion on drug delivery · 2021Review
- Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases.Molecular therapy : the journal of the American Society of Gene Therapy · 2019Review
- Barriers to inhaled gene therapy of obstructive lung diseases: A review.Journal of controlled release : official journal of the Controlled Release Society · 2016Review
- Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2013Review
- N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine.Nanomedicine (London, England) · 2011Article
- Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis.PloS one · 2009Article
- Extracellular barriers in respiratory gene therapy.Advanced drug delivery reviews · 2009Review
- Microcapsules ejecting nanosized species into the environment.Journal of the American Chemical Society · 2008Article
- Three-dimensional fluorescence recovery after photobleaching with the confocal scanning laser microscope.Biophysical journal · 2003Article
- Targeting of Synthetic Gene Delivery Systems.Journal of biomedicine & biotechnology · 2003Article
- Pegylated GL67 lipoplexes retain their gene transfection activity after exposure to components of CF mucus.Gene therapy · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to examine the extent to which plasmid DNA (pDNA) complexed to cationic liposomes diffuse through cystic fibrosis (CF) sputum. The influence of the physical and chemical properties of the sputa was evaluated. We further investigated whether degradation of the sputa by recombinant human DNase I (rhDNase I) enhances the transport.
methodsThe transport of lipoplexes was studied through layers of CF sputa placed between the donor and acceptor compartment of vertical diffusion chambers. The content of the acceptor compartment was analyzed by confocal fluorescence microscopy, gel electrophoresis and Southern blotting. The influence of linear DNA present in the CF sputa on the size, surface charge and gene expression of the lipoplexes was evaluated by dynamic light scattering, particle electrophoresis and transfection experiments.
resultsLipoplexes were observed in the acceptor compartments. However, the percent of diffused lipoplexes was low: 0.05/% +/- 0.01%. It was found that both steric obstruction by the sputa as well as the long" distance the lipoplexes have to travel were responsible for this low transport. Surprisingly, the transport occurred better through more viscoelastic sputa. The DNA in the CF sputa also retarded the transport, which was attributed to aggregation of the lipoplexes by the DNA. Finally, rhDNase I moderately enhanced the diffusion of lipoplexes.
conclusionsCF sputum drastically retards the diffusion of lipoplexes. DNA in the sputa aggregates the lipoplexes. This may lower the transport of lipoplexes through the sputa and gene expression. Pretreatment of CF patients with rhDNase I may enhance the efficiency of CF gene therapy, as it allows a better transport of the lipoplexes through the sputum and as it partly removes the sputum which will result in a thinner sputum layer on top of the epithelial cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.